Fox Business - The Power to Prosper
Search Site

Gilead Sciences

Stocks to watch: CMG, DIS

Rosenthal Wealth Management Group President Larry Rosenthal, Spectrum Management Group Managing Partner Bob Phillips, OptionPit.com founder Mark Sebastian and FBN’s Nicole Petallides on the state of the markets.

Read More

  1. What to expect from pharma

    Robert W. Baird & Co. senior analyst Brian Skorney on what investors can expect from pharma in the second quarter.

  2. Gilead Profit Triples On Hepatitis C Drug Revenue

    Gilead Sciences Inc (NASDAQ:GILD), which ignited a fierce debate over prescription drug prices, said its new $1,000 hepatitis C pill generated quarterly sales of $2....

  3. Gilead Beats Expectations; Sovaldi Sales Hit $2.3 Bln

    Gilead Sciences Inc. reported late Tuesday its first-quarter net income rose to $2.23 billion, or $1.33 per diluted share, from $722.2 million, or 43 cents per dilut...

  4. Rallying Ahead of Earnings

    A handful of companies due to report earnings this afternoon are rallying into the close.  Note that biotechs Gilead Sciences and Amgen are advancing the most:Rallyi...

  5. After Shaky Start, Weibo Jumps in Nasdaq Debut

    Chinese Twitter (NYSE:TWTR) clone Weibo (NASDAQ:WB) closed 19% above its U.S. initial public offering price on Thursday after slashing the offering size in an attemp...

  6. Has Momentum Investing Lost its Mojo?

    Former high flying industry sectors like biotech (NASDAQGIDS:IBB) and social media stocks (NYSEARCA:SOCL) have crashed between 14-16% over the past month. Have hot m...

  7. Markets sell off, biotech sinks

    Wall Financial Group President Michael Wall, Harris Financial Group managing partner Jamie Cox, OneStopOption’s Alan Knuckman and FBN’s Jo Ling Kent break down this week’s market action.

  8. Downgrades weigh on Aeropostale shares

    FBN’s Nicole Petallides on Aeropostale and Gilead Sciences .

  9. Don't Panic Over the Recent Tech Turmoil

    U.S. investors have understandably been disturbed by the dramatic selling that has slapped down high-flying momentum stocks in the Internet and biotech sectors.Tesla...

  10. What to expect from earnings

    Mendon Capital Advisors president Anton Schutz and Raymond James chief investment strategist Jeff Saut give their outlook for earnings season.

  11. Meet Nasdaq Composite 2.0

    The Nasdaq Composite crossed back over the 4000 threshold earlier this year for the first time in 14 years, taking the index back to levels unseen since the heady da...

  12. Despite S&P 500's New High, Stocks Face Challenges

    Stocks ended the first quarter with a big rally; the Standard & Poor's 500 Index actually closed -- barely -- at a new high. The fact is, however, that the market ov...

  1. Market check: TSLA, NFLX, GILD, FB

    FBN’s Nicole Petallides with the latest on the markets.

  2. Where to find value in today’s market

    Silvant Capital Management managing director Michael Sansoterra gives insight into today’s market.

  3. Sectors seeing growth now

    Brick Investment Partners managing director Chris Thorpe and Landcolt Capital founder Todd Schoenberger discuss their outlook for the economy and markets.

  4. Dow hits all-time high of 17,000

    Stifel Nicolaus portfolio manager Chad Morganlander says the Dow hitting 17,000 shows the economy is on the mend.

  5. Oracle’s $10B bond

    FBN’s Liz MacDonald on Oracle’s $10B bond offering.

  6. Health care sector drags on the S&P

    FBN’s Liz MacDonald with an update on stocks.

  7. Second tech bubble?

    Deutsche Bank senior U.S. economist Carl Riccadonna and BMO Capital Markets chief investment strategist Brian Belski on whether we’re in the second tech bubble in 15 years.

‹ Prev12345Next ›
Freebase CC-BY
Source: Gilead Sciences on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL